Insights into the application of let-7 family as promising biomarker in cancer screening

Tumor Biology

Volumn 36, Issue 7, 2015, Pages 5233-5239

  Dai, Ying ^a   Wang, Daqing ^b   Tian, Xin ^a   Zhang, Li ^a   Sui, Chengguang ^a   Meng, Fandong ^a   Jiang, Shengyi ^a   Liu, Yunpeng ^a   Jiang, Youhong ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b Key Laboratory of Reproductive Health and Medical Genetics   (China)

Author keywords

Cancers; Let 7 family; Meta analysis; MicroRNAs; Screening

Indexed keywords

MICRORNA; MICRORNA LET 7; UNCLASSIFIED DRUG; MIRNLET7 MICRORNA, HUMAN; TUMOR MARKER;

AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER SCREENING; CANCER SURVIVAL; CAUSE OF DEATH; DIAGNOSTIC ACCURACY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MOUTH SQUAMOUS CELL CARCINOMA; NON INVASIVE PROCEDURE; NON SMALL CELL LUNG CANCER; OVARY CARCINOMA; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; RETINOBLASTOMA; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW; VALIDATION PROCESS; ADULT; AGED; BIOSYNTHESIS; DIAGNOSTIC USE; EARLY DIAGNOSIS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MALE; META ANALYSIS; MIDDLE AGED; NEOPLASMS; PATHOLOGY; PROGNOSIS; SURVIVAL;

ADULT; AGED; EARLY DETECTION OF CANCER; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASMS; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84938206598     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3180-1     Document Type: Article

References (43)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29. doi:10.3322/caac.21208.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. doi:10.3322/caac.20107.
3. Leone G, Fianchi L, Pagano L, Voso MT. Incidence and susceptibility to therapy-related myeloid neoplasms. Chem Biol Interact. 2010;184:39–45. doi:10.1016/j.cbi.2009.12.013.
4. Sessions DG, Spector GJ, Lenox J, Haughey B, Chao C, Marks J. Analysis of treatment results for oral tongue cancer. Laryngoscope. 2002;112:616–25. doi:10.1097/00005537-200204000-00005.
5. Wang Q, Wu X, Wu T, Li GM, Shi Y. Clinical significance of RKIP mRNA expression in non-small cell lung cancer. Tumour Biol. 2014;35:4377–80. doi:10.1007/s13277-013-1575-4.
6. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–76. doi:10.1053/j.gastro.2007.04.061.
7. Wittmann J, Jack HM. Serum microRNAs as powerful cancer biomarkers. Biochim Biophys Acta. 1806;2010:200–7. doi:10.1016/j.bbcan.2010.07.002.
8. Dominioni L, Imperatori A, Rovera F, Ochetti A, Torrigiotti G, Paolucci M. Stage I nonsmall cell lung carcinoma: analysis of survival and implications for screening. Cancer. 2000;89:2334–44.
9. Oken MM, Marcus PM, Hu P, Beck TM, Hocking W, Kvale PA, et al. Baseline chest radiograph for lung cancer detection in the randomized prostate, lung, colorectal and ovarian cancer Screening Trial. J Natl Cancer Inst. 2005;97:1832–9. doi:10.1093/jnci/dji430.
10. Henschke CI, Yankelevitz DF, Libby DM, Pasmantier MW, Smith JP, Miettinen OS. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med. 2006;355:1763–71. doi:10.1056/NEJMoa060476.
11. Mascalchi M, Belli G, Zappa M, Picozzi G, Falchini M, Della Nave R, et al. Risk-benefit analysis of X-ray exposure associated with lung cancer screening in the Italung-CT trial. AJR Am J Roentgenol. 2006;187:421–9. doi:10.2214/AJR.05.0088.
12. Taplin S, Abraham L, Barlow WE, Fenton JJ, Berns EA, Carney PA, et al. Mammography facility characteristics associated with interpretive accuracy of screening mammography. J Natl Cancer Inst. 2008;100:876–87. doi:10.1093/jnci/djn172.
13. Neri E, Faggioni L, Cerri F, Turini F, Angeli S, Cini L, et al. CT colonography versus double-contrast barium enema for screening of colorectal cancer: comparison of radiation burden. Abdom Imaging. 2010;35:596–601. doi:10.1007/s00261-009-9568-x.
14. Lumachi F, Brandes AA, Ermani M, Bruno G, Boccagni P. Sensitivity of serum tumor markers CEA and CA 15-3 in breast cancer recurrences and correlation with different prognostic factors. Anticancer Res. 2000;20:4751–5.
15. Hanash SM, Baik CS, Kallioniemi O. Emerging molecular biomarkers—blood-based strategies to detect and monitor cancer. Nat Rev Clin Oncol. 2011;8:142–50. doi:10.1038/nrclinonc.2010.220.
16. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75:843–54.
17. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.
18. Cho WC. OncomiRs: the discovery and progress of microRNAs in cancers. Mol Cancer. 2007;6:60. doi:10.1186/1476-4598-6-60.
19. Nana-Sinkam P, Croce CM. MicroRNAs in diagnosis and prognosis in cancer: what does the future hold? Pharmacogenomics. 2010;11:667–9. doi:10.2217/pgs.10.57.
20. Taft RJ, Pang KC, Mercer TR, Dinger M, Mattick JS. Non-coding RNAs: regulators of disease. J Pathol. 2010;220:126–39. doi:10.1002/path.2638.
21. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435:834–8. doi:10.1038/nature03702.
22. Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH, Lee MJ, et al. The microRNA spectrum in 12 body fluids. Clin Chem. 2010;56:1733–41. doi:10.1373/clinchem.2010.147405.
23. Abd-El-Fattah AA, Sadik NA, Shaker OG, Aboulftouh ML. Differential microRNAs expression in serum of patients with lung cancer, pulmonary tuberculosis, and pneumonia. Cell Biochem Biophys. 2013;67:875–84. doi:10.1007/s12013-013-9575-y.
24. Ruby JG, Jan C, Player C, Axtell MJ, Lee W, Nusbaum C, et al. Large-scale sequencing reveals 21U-RNAs and additional microRNAs and endogenous siRNAs in C. elegans. Cell. 2006;127:1193–207. doi:10.1016/j.cell.2006.10.040.
25. Pasquinelli AE, Reinhart BJ, Slack F, Martindale MQ, Kuroda MI, Maller B, et al. Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature. 2000;408:86–9. doi:10.1038/35040556.
26. Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE, et al. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature. 2000;403:901–6. doi:10.1038/35002607.
27. Heneghan HM, Miller N, Kelly R, Newell J, Kerin MJ. Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. Oncologist. 2010;15:673–82. doi:10.1634/theoncologist. 2010-0103.
28. Jeong HC, Kim EK, Lee JH, Lee JM, Yoo HN, Kim JK. Aberrant expression of let-7a miRNA in the blood of non-small cell lung cancer patients. Mol Med Rep. 2011;4:383–7. doi:10.3892/mmr.2011.430.
29. Liu SS, Wang YS, Sun YF, Miao LX, Wang J, Li YS, et al. Plasma microRNA-320, microRNA-let-7e and microRNA-21 as novel potential biomarkers for the detection of retinoblastoma. Biomed Rep. 2014;2:424–8. doi:10.3892/br.2014.246.
30. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155:529–36. doi:10.7326/0003-4819-155-8-201110180-00009.
31. Mitchell AJ, Vaze A, Rao S. Clinical diagnosis of depression in primary care: a meta-analysis. Lancet. 2009;374:609–19. doi:10.1016/S0140-6736(09)60879-5.
32. Swets JA. Measuring the accuracy of diagnostic systems. Science. 1988;240:1285–93.
33. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58. doi:10.1002/sim.1186.
34. Dinnes J, Deeks J, Kirby J, Roderick P. A methodological review of how heterogeneity has been examined in systematic reviews of diagnostic test accuracy. Health Technol Assess. 2005;9:1–113.
35. Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol. 2005;58:882–93. doi:10.1016/j.jclinepi.2005.01.016.
36. Zheng H, Zhang L, Zhao Y, Yang D, Song F, Wen Y, et al. Plasma miRNAs as diagnostic and prognostic biomarkers for ovarian cancer. PLoS One. 2013;8:e77853. doi:10.1371/journal.pone.0077853.
37. Lee CH, Kuo WH, Lin CC, Oyang YJ, Huang HC, Juan HF. MicroRNA-regulated protein-protein interaction networks and their functions in breast cancer. Int J Mol Sci. 2013;14:11560–606. doi:10.3390/ijms140611560.
38. Maclellan SA, Lawson J, Baik J, Guillaud M, Poh CF, Garnis C. Differential expression of miRNAs in the serum of patients with high-risk oral lesions. Cancer Med. 2012;1:268–74. doi:10.1002/cam4.17.
39. Chen ZH, Zhang GL, Li HR, Luo JD, Li ZX, Chen GM, et al. A panel of five circulating microRNAs as potential biomarkers for prostate cancer. Prostate. 2012;72:1443–52. doi:10.1002/pros.22495.
40. Mahn R, Heukamp LC, Rogenhofer S, von Ruecker A, Muller SC, Ellinger J. Circulating microRNAs (miRNA) in serum of patients with prostate cancer. Urology. 2011;77:1265 e9-16. doi:10.1016/j.urology.2011.01.020.
41. Rosenfeld RM, Shiffman RN. Clinical practice guidelines: a manual for developing evidence-based guidelines to facilitate performance measurement and quality improvement. Otolaryngol Head Neck Surg. 2006;135:S1–28. doi:10.1016/j.otohns.2006.06.1277.
42. Stengel D, Bauwens K, Sehouli J, Ekkernkamp A, Porzsolt F. A likelihood ratio approach to meta-analysis of diagnostic studies. J Med Screen. 2003;10:47–51.
43. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer. 2005;93:387–91. doi:10.1038/sj.bjc.6602678.